AbCellera Biologics Inc. (ABCL): Cash & Equivalents
$128.51M
As of 2025-12-31
$120.06M
As of 2026-06-30
-30.7%
3-year compound annual growth
-26.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.51M | -17.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $156.32M | +17.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $133.32M | -65.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $386.54M | -18.8% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $476.14M | -19.9% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $594.12M | n/a | 2022-02-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $128.51M | -17.8% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $628.11M | -28.6% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $58.45M | +52.4% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $25.94M | +73.7% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
Compare ABCL, CTMX, BCYC, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗